Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04262375
Title A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University Health Network, Toronto
Indications

renal cell carcinoma

lung non-small cell carcinoma

Therapies

Durvalumab + Oleclumab

Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field